Tanushree Jain
Stock Analyst at Petra Capital
(4.56)
# 962
Out of 4,600 analysts
105
Total ratings
39.3%
Success rate
27.8%
Average return
Main Sectors:
Stocks Rated by Tanushree Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: COV Cleo Diagnostics Ltd | Maintained: Buy | $1.15 → $1.26 | $0.34 | +276.12% | 4 | Feb 18, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Maintained: Buy | $31.38 → $29.96 | $21.87 | +36.99% | 10 | Feb 5, 2026 | |
| ASX: AYA Artrya Limited | Maintained: Buy | $3.51 → $6.27 | $4.52 | +38.72% | 8 | Feb 2, 2026 | |
| ASX: DXB Dimerix Limited | Maintained: Buy | $1.46 | $0.30 | +394.92% | 12 | Feb 1, 2026 | |
| ASX: AGN Argenica Therapeutics Limited | Maintained: Buy | $0.63 → $0.64 | $0.15 | +326.67% | 12 | Jan 28, 2026 | |
| ASX: NUZ Neurizon Therapeutics Limited | Maintained: Buy | $0.52 → $0.56 | $0.06 | +803.23% | 9 | Oct 7, 2025 | |
| ASX: OCC Orthocell Limited | Maintained: Buy | $1.28 → $1.32 | $0.75 | n/a | 6 | Oct 23, 2024 | |
| ASX: BOT Botanix Pharmaceuticals Limited | Maintained: Hold | $0.17 | $0.02 | n/a | 1 | Dec 6, 2023 | |
| ASX: IMM Immutep Limited | Maintained: Buy | $1.00 → $1.28 | $0.05 | n/a | 9 | May 29, 2023 | |
| ASX: MSB Mesoblast Limited | Maintained: Buy | $3.45 | $2.13 | n/a | 13 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $0.37 | $0.02 | n/a | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.20 → $2.20 | $0.05 | n/a | 6 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $0.09 → $0.14 | $0.03 | n/a | 4 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.97 → $7.10 | $0.49 | n/a | 5 | Nov 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.90 → $4.40 | $0.01 | n/a | 3 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1.89 → $2.20 | $0.80 | n/a | 2 | Sep 2, 2020 |
Cleo Diagnostics Ltd
Feb 18, 2026
Maintained: Buy
Price Target: $1.15 → $1.26
Current: $0.34
Upside: +276.12%
Neuren Pharmaceuticals Limited
Feb 5, 2026
Maintained: Buy
Price Target: $31.38 → $29.96
Current: $21.87
Upside: +36.99%
Artrya Limited
Feb 2, 2026
Maintained: Buy
Price Target: $3.51 → $6.27
Current: $4.52
Upside: +38.72%
Dimerix Limited
Feb 1, 2026
Maintained: Buy
Price Target: $1.46
Current: $0.30
Upside: +394.92%
Argenica Therapeutics Limited
Jan 28, 2026
Maintained: Buy
Price Target: $0.63 → $0.64
Current: $0.15
Upside: +326.67%
Neurizon Therapeutics Limited
Oct 7, 2025
Maintained: Buy
Price Target: $0.52 → $0.56
Current: $0.06
Upside: +803.23%
Orthocell Limited
Oct 23, 2024
Maintained: Buy
Price Target: $1.28 → $1.32
Current: $0.75
Upside: n/a
Botanix Pharmaceuticals Limited
Dec 6, 2023
Maintained: Hold
Price Target: $0.17
Current: $0.02
Upside: n/a
Immutep Limited
May 29, 2023
Maintained: Buy
Price Target: $1.00 → $1.28
Current: $0.05
Upside: n/a
Mesoblast Limited
Nov 17, 2021
Maintained: Buy
Price Target: $3.45
Current: $2.13
Upside: n/a
Jul 30, 2021
Maintained: Buy
Price Target: $0.37
Current: $0.02
Upside: n/a
Jun 29, 2021
Maintained: Buy
Price Target: $3.20 → $2.20
Current: $0.05
Upside: n/a
Jan 11, 2021
Upgraded: Buy
Price Target: $0.09 → $0.14
Current: $0.03
Upside: n/a
Nov 2, 2020
Maintained: Buy
Price Target: $8.97 → $7.10
Current: $0.49
Upside: n/a
Oct 27, 2020
Maintained: Buy
Price Target: $4.90 → $4.40
Current: $0.01
Upside: n/a
Sep 2, 2020
Maintained: Buy
Price Target: $1.89 → $2.20
Current: $0.80
Upside: n/a